Study Group: Neurologists
Council Members in this Study Group: 1866
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Walter Carlini, MD, PhD
Neurologist
Medford Neurological Clinic, Inc.
Walter Carlini, MD, PhD, is a General Neurologist at Medford Neurological Clinic in Oregon. His clinical interests include stroke, epilepsy, migraine, dementia, movement disorders, and multiple sclerosis. Dr. Carlini has expertise in clinical neurophysiology and in the use of botulinum toxin injections...
Daniel Wynn, MDDirector of Clinical Research
CONSULTANTS IN NEUROLOGY LTDDaniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke,chronic...
- Robert Green, MD
Professor of Neurology and Epidemiology
Boston University School of Medicine - CCRobert C. Green, MD, MPH, is Professor of Neurology at Boston University School of Medicine (BUSM) and Professor of Epidemiology at Boston University School of Public Health. He is Co-Director of the Memory Assessment Clinics at Boston Medical Center, Associate Director and Clinical Core Leader ofthe...
- Stephen Landy, MD
Director of Neurology
Wesley Headache ClinicStephen Landy, MD, is the Director of Neurology at Wesley Headache Clinic and Clinical Professor in Department of Neurology at University of Tennessee. Dr. Landy is certified by the National Board of Medical Examiners, the American Board of Psychiatry and Neurolgy. Also, he is certified by the National...
- Peter Rieckmann, MD
Professor of Neurology and MS Research Chair
UNIVERSITY OF BRITISH COLUMBIAPeter Rieckmann, MD, FRCPC, is a Professor of Neurology and MS Research Chair at the University of British Columbia, Canada. He has established the Western Canadian MS Research and Training Center at UBC, Vancouver and is member of the EndMS steering committee (Canadian MS society). He has served as...
GLG NewsSM Analyses by this Study Group's Leading Experts (?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
a natural response by competitor
October 26, 2009
Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s disease | www.pipelinereview.com
1. Requip XL will be coming out soon so BI had to come up with Mirapex once daily SR.2. Once daily dosing is probably better for our Parkinson's patients as this will provide continuous dopaminergic stimulation with less fluctuation.
-
Fampridine Clears Major Hurdle at FDA Review Panel
October 14, 2009
FDA Panel Backs Proposed Acorda Multiple Sclerosis Drug (fampridine) To Improve Walking | online.wsj.com
Fampridine has been recommended for approval on 10/14. There are several more steps needed at the regulatory level, but the medicine is back on the approval track after a critical pre-meeting FDA report raised serious criticisms.
-
Fampridine's FDA Pre-Meeting Report Raises Concerns About Efficacy and Safety
October 12, 2009
FDA Questions Efficacy of Acorda's MS Drug (Fampridine SR) | www.thestreet.com
The FDA released it's pre-meeting review online this past Friday, and clearly had some concerns. Acorda will need to address these very thoroughly and seriously.
-
Government Run Health Insurance Fails
October 9, 2009
Fate of Government-Run Health Insurance May Rest in Obama's Hands | www.foxnews.com
The Senate Finance Committee rejected the "public option" for government-run health insurance not once but twice. Even some democrats were wary of the public option. These failures underscore the fact that the United States is wrestling with a fundamental shift in thinking about the proper role of...
-
FTY720 for Relapsing forms of MS
October 9, 2009
Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression | www.pipelinereview.com
Fingolimod must be doing something right, because the latest study shows significant reduction in disability progression and relapse rates, even at the small doses tested (0.5 mg/d). Novartis is poised to submit an IND at the end of 2009 (very soon). The results of the FREEDOMS trial suggest that...
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Professor
- Director
- Owner
- Physician - Department Chair
Related Study Groups
| Study Group Name | No. Members |
|---|---|
| Neurologists (US) | 1083 |
| Neurologists (EU) | 561 |
| Attending-Level Neurologists at Academic Medical Centers (US) | 543 |
| Neurologists who Treat Epilepsy (US) | 340 |
| Neurologists who Treat Neuromuscular Disorders (US) | 234 |
| Neurologists who Treat Alzheimer's Disease (US) | 204 |
| Vascular Neurologists (US) | 166 |